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Abstract
Background: Quantitative neuromuscular monitoring is the gold standard to detect postoperative residual curarization
(PORC). Many anesthesiologists, however, use insensitive, qualitative neuromuscular monitoring or unreliable, clinical tests.
Goal of this multicentre, prospective, double-blinded, assessor controlled study was to develop an algorithm of muscle
function tests to identify PORC.
Methods: After extubation a blinded anesthetist performed eight clinical tests in 165 patients. Test results were correlated
to calibrated electromyography train-of-four (TOF) ratio and to a postoperatively applied uncalibrated
acceleromyography. A classification and regression tree (CART) was calculated developing the algorithm to identify PORC.
This was validated against uncalibrated acceleromyography and tactile judgement of TOF fading in separate 100 patients.
Results: After eliminating three tests with poor correlation, a model with four tests (r = 0.844) and uncalibrated
acceleromyography (r = 0.873) were correlated to electromyographical TOF-values without losing quality of prediction.
CART analysis showed that three consecutively performed tests (arm lift, head lift and swallowing or eye opening) can
predict electromyographical TOF. Prediction coefficients reveal an advantage of the uncalibrated acceleromyography in
terms of specificity to identify the EMG measured train-of-four ratio < 0.7 (100% vs. 42.9%) and <0.9 (89.7% vs. 34.5%)
compared to the algorithm. However, due to the high sensitivity of the algorithm (100% vs. 94.4%), the risk to overlook
an awake patient with a train-of-four ratio < 0.7 was minimal. Tactile judgement of TOF fading showed poorest
sensitivity and specifity at train of four ratio < 0.9 (33.7%, 0%) and <0.7 (18.8%, 16.7%).
Conclusions: Residual neuromuscular blockade can be detected by uncalibrated acceleromyography and if not available
by a pathway of four clinical muscle function tests in awake patients. The algorithm has a discriminative power comparable
to uncalibrated AMG within TOF-values >0.7 and <0.3.
Trial registration: Clinical Trials.gov (principal investigator’s name: CU, and identifier: NCT03219138) on July 8, 2017.
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Background
Use of neuromuscular monitoring together with pharmaco-
logical reversal of neuromuscular blocking drugs in the op-
eration room is able to reduce the incidence of residual
paralysis in patients arriving in the postoperative care unit
(PACU), especially when a quantitative monitoring device
is used [1, 2]. Unfortunately, quantitative neuromuscular
monitoring is neither available in many operating rooms
nor regularly used worldwide [3–6]. Many anaesthesiology
societies do not reinforce quantitative neuromuscular mon-
itoring [7–9]. Therefore, in everyday practice, anaesthesiolo-
gists often prefer simple peripheral nerve stimulators (PNS)
to assess fading qualitatively. However if there is no tactile
fading in TOF and double burst stimulation a 50% risk of
actual TOF ratio < 0.7 remains. Appeals to use quantitative
techniques on a routine basis are not heard and lead to
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more resistance rather than compliance [10–12]. This di-
lemma will most likely not change fundamentally in the
near future. Therefore, we will continue to see patients with
residual neuromuscular block in the PACU.
Neuromuscular monitoring in awake patients has so far
not been validated [13]. Rejection of quantitative neuro-
muscular monitoring in the PACU is, therefore, more
understandable than its widespread intraoperative denial.
In other words, it cannot be expected that anaesthetists,
who do not rely on quantitative neuromuscular monitor-
ing during anaesthesia, change their approach after an-
aesthesia. Nevertheless, studies investigating postoperative
residual paralysis used neuromuscular monitoring in a
postoperative setting [14–18]. Although these studies
could demonstrate accordance between acceleromyogra-
phy (AMG) and clinical signs of muscle weakness, there is
no standard diagnostic tool for postoperative residual
neuromuscular block [14–18].
In this multicentre, prospective, double-blinded, asses-
sor controlled study we developed and validated an algo-
rithm of clinical muscle function tests to identify residual
paralysis in awake patients after anaesthesia. First, we
tested a set of clinical muscle function tests with train-of-
four ratio (TOFR) measured simultaneously by calibrated
electromyography (EMG) at the adductor pollicis muscle.
Second, the battery of tests was reduced to an algorithm,
which becomes applicable in a clinical setting. Finally, an
uncalibrated AMG, the algorithm, and qualitative tactile
neuromuscular monitoring were validated in a separate
set of awake patients by comparison with calibrated EMG.
Methods
Patients
After approval by the local ethics committees (main eth-
ical committee, Technische Universität München,
Germany; protocol N° 1783/07) of the six participating
study centres and written informed consent, 318 patients
(ASA 1–2) were enrolled in the study. The patients were
scheduled for elective low risk surgical procedures (e.g.
laparoscopic abdominal procedures; orthopedic and minor
visceral surgery). Patients were excluded from the study if
they currently participated in another study, if their body
mass index was over 30, if age was under 18 or over
65 years, if they had a history of neuromuscular diseases
or gastro-esophageal reflux disease. A set of 200 patients
served as data pool to develop the algorithm of clinical
muscle function tests to identify residual neuromuscular
block. In another set of 118 patients, the developed tool
was validated (Fig. 1, CONSORT flow diagram). Study was
performed between 2008 and 2009.
Procedure
After arrival to the operating room, standard monitoring
was applied which included electrocardiography, pulse
oximetry, automatic non-invasive blood-pressure meas-
urement, oropharyngeal temperature and capnography.
Patients were anaesthetized with remifentanil and pro-
pofol and ventilated with 100% oxygen using a facemask.
Neuromuscular function was monitored according to
international consensus guidelines, using evoked EMG of
the adductor pollicis muscle with a NMT module in a S/5
GE Datex Light monitor (GE Datex Medical Instrumenta-
tion, Inc., Tewksbury, MA, USA) by a non-blinded investi-
gator [19]. The blinded anaesthesiologist was unable to
see the data on the monitor. In brief, the forearm was
immobilised and surface skin electrodes were placed over
the ulnar nerve along the forearm. Following calibration,
the ulnar nerve was stimulated with supramaximal train-
of-four (TOF) stimulation at 20s intervals and the evoked
electromyogram of the adductor pollicis muscle was re-
corded. The neuromuscular transmission and its suppres-
sion is described by parameters related to the TOF
stimulation patterns, i.e., the response to the first stimula-
tion related to the baseline values (T1/T0) and the TOFR.
Following 3 min of stabilization of the EMG recording,
atracurium 0.5 mg/kg was intravenously injected and the
trachea intubated. Anaesthesia was maintained with
remifentanil 0.05–1.0 μg/kg/min and desflurane 0.9–1.1
MAC (age adapted) in 40–50% oxygen. Ventilation was
controlled to maintain normocapnia (35–45 mmHg).
During surgery, the (blinded) attending anaesthesiologist
administered maintenance doses of atracurium 0.1 mg/
kg according to clinical needs, i.e. without knowing the
TOFR. Oropharyngeal temperature was kept ≥36 °C by
forced air warming devices.
After end of surgery, the blinded anaesthesiologist
stopped remifentanil infusion and desflurane inhalation.
The patients’ trachea was extubated according to clinical
judgement (sufficient alertness, cooperation, sufficient
spontaneous ventilation), without knowledge of the
quantitatively monitored EMG values.
Immediately after extubation the blinded anaesthesi-
ologist tested the patient in the operating room. The
postoperative evaluation of neuromuscular function con-
sisted of eight clinical tests applied in a random order
(Table 1). Thereafter, an uncalibrated AMG was started
on the contralateral arm (TOF-Watch-Monitor; MIPM
GmbH, Mammendorf, Germany). To avoid movement
artefacts, the patient’s arm and the other four fingers
were fixed to the arm rest. The response of the adductor
pollicis muscle to ulnar nerve TOF stimulation (50 mA,
2 Hz, 200 ms) was measured. During the validation of
the developed algorithm the anaesthesiologist had to
judge tactile fading of the adductor pollicis before the
acceleration transducer was applied to the distal phalanx
of the thumb.
Neuromuscular monitoring in awake patients is prone
to artefacts. Therefore, a second blinded anaesthesiologist
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thoroughly reviewed the EMG files afterwards. In patients
where either no data could be obtained or the TOFR
dropped by more than 20% at least twice during the clin-
ical muscle function tests, the respective data was
excluded from analysis (Fig. 2).
If a patient had any clinical signs of neuromuscular dys-
function, reversal with neostigmine 40 μg/kg preceded by
glycopyrrolate 7 μg/kg was administered. Due to safety is-
sues, the clinical muscle function tests and the AMG mea-
surements were repeated within 30 min. Then, patients
were transferred to the PACU, where circulatory, cardiac,
and respiratory function were monitored for at least 2 h
before the patients were discharged from the PACU.
Data management and statistical analyses
We compared tools (uncalibrated AMG, tactile evalu-
ation following peripheral nerve stimulation and algo-
rithm of muscle function tests) with a gold standard
(calibrated EMG). Accordingly, we only analysed patients’
data whose EMG signal was stable after extubation.
CART technique (Classification And Regression Tree)
was used to create an algorithm with a combination of
the tests, which qualified as an optimized predictor of
the EMG. Briefly, CART divides the entire sample step
by step into smaller binary subgroups. In each step, the
sample is divided into two subgroups by investigating all
possible splits and using the split with the best separ-
ation with respect to the dependent variable [20]. Both
subgroups are independently analysed in the same way
until either no significant split can be performed or the
sample becomes too small. The dependent variable was
the TOFR of the EMG-measurement.
To allow the comparison of the model based on func-
tion tests with the metric TOFR-values of EMG or AMG
we dichotomised the TOFR in a way clinical decisions are
typically made. As cut-off we defined a neuromuscular
function of an EMG-measured TOFR = 0.9 and the
formerly accepted level of TOFR = 0.7. The tactile TOFR
was dichotomised in “fading palpable” or “fading not palp-
able”. The overall performance of the models for the
Fig. 1 CONSORT Flow Diagram
Table 1 Clinical tests to evaluate the neuromuscular function. The tests were performed after extubation in the awake, alert, and
cooperative patient
Test Evaluation Scores
Open eyes Time able to keep eyes open [s] 0–5
Diplopic image Appearance of diplopic images [yes = 0; no = 1] 0–1
Stick out tongue Time able to stick out tongue [s] 0–5
Spatula pressure Subjective strength necessary to pull out the spatula against the
patient’s occlusion efforts
0–3
Head lift Time able to elevate the head from the pillow in supine position [s] 0–5
Arm lift Time able to elevate the arm to 45° in supine position [s] 0–5
Press hand Subjective strength of the patient pressing the investigator’s hand 0–3
Swallowing 20 ml of water Impossible = 0, possible with choking = 1, possible, but with problems = 2,
possible without any hindrance = 3
0–3
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different cut-off levels was calculated in form of receiver-
operated characteristics (ROC). The areas under the
curves (AUC) of the ROC curves were used as a measure
for the discriminative power of the models.
For validation of the developed tools (uncalibrated
AMG, tactile evaluation following nerve stimulation and
algorithm of muscle function tests), sensitivity and speci-
ficity with exact binomial confidence intervals were
calculated. Sample size was calculated based on the as-
sumptions that the algorithm most probably will not be
able to predict TOFR ≥0.9, but a TOFR ≥0.7 is a level of
recovery of the neuromuscular function possibly sufficient
to avoid major complications. Therefore, we primarily fo-
cused on a high sensitivity (>90%) with an accuracy of the
estimate <10%, resulting in a necessary sample of at least
36 patients with TOFR <0.7 and at least 36 patients with
TOFR ≥0.7. In the development cohort, 49% of patients
had a TOFR ≥0.7 and 51% had a TOFR <0.7, 95%-confi-
dence intervals reached from 41% to 59%. Therefore, we
decided to include 100 patients for the validation assum-
ing to result in at least 40 patients with TOFR <0.7 as well
as at least 40 patients with TOFR ≥0.7.
The risk to overlook patients with a residual neuromus-
cular block with the three tools depends on the sensitivity
(sens) and specificity (spec) of the tools and the prevalence
(p(ε)) at the respective TOFR level ε. Since the validation
part of the study was not designed to evaluate the preva-
lence of postoperative residual neuromuscular block, the
risk (P) to overlook a residual block can be calculated
dependent on the unknown prevalence only:
P TOFEMG < ε TOFRtool >j εð Þ
¼ p εð Þ  1−sensð Þ
p εð Þ  1−sensð Þ þ 1−p εð Þð Þ  spec
Statistics were performed using STATA (StataCorpLP,




For the algorithm development, 200 patients were en-
rolled (age: 41 ± 14 years; weight: 79 ± 23 kg; body mass
index BMI: 25 ± 3 kg/m2). In 26 patients the EMG sig-
nal showed significant jerky leaps during emergence
from anaesthesia (see e.g. Fig. 2), 9 patients had intraoral
operations that did not allow swallowing water and the
spatula pressure test. In 165 patients the EMG signal qual-
ity remained stable and the complete set of tests could be
performed. The values of the two neuromuscular monitor-
ing techniques and times are given in Table 2. Following
assessment, 114 of the 165 patients required reversal of
Fig. 2 Example of an instable EMG signal during return of consciousness. After moving the arm the cable was disconnected. The patient did not
accept connecting the EMG again or the AMG on the contralateral arm
Table 2 The values of the two neuromuscular monitoring techniques (EMG and AMG) during the algorithm development and
validation at the different time points during the study. Values are given as mean ± SD (ranges)
Algorithm development (n = 165) Algorithm validation(n = 100)
T1/T0 after calibration(EMG) 0.96 ± 0.02(0.90–1.01) 0.96 ± 0.02(0.91–1.00)
T1/T0 at extubation(EMG) 0.64 ± 0.24(0.10–1.08) 0.62 ± 0.20(0.11–1.02)
TOFR at extubation(EMG) 0.57 ± 0.33(0.00a – 1.03) 0.47 ± 0.25(0.00a – 1.00)
T1/T0 at assessment(EMG) 0.68 ± 0.22(0.12–1.11) 0.66 ± 0.19(0.23–1.20)
TOFR at assessment(EMG) 0.61 ± 0.31(0.00a – 1.15) 0.53 ± 0.25(0.00a – 0.99)
TOFR at assessment(AMG) 0.63 ± 0.32(0.00a – 1.20) 0.57 ± 0.25(0.00a – 1.00)
TOFR after 30 min PACU(AMG) 0.96 ± 0.09b(0.66–1.26) 0.97 ± 0.09(0.92–1.02)
EMG electromyography, AMG acceleromyography, PACU post anaesthesia care unit
aT2/T0 > 0, i.e. reappearance of the second twitch response; b (n = 133)
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the neuromuscular block with neostigmine. After
30 min, no patient had any clinical sign of neuromuscu-
lar weakness, i.e. all clinical tests could be performed
without any limitation.
Patients with better muscle function tests had a ten-
dency towards higher TOFRs. No single test was an
acceptable predictor of the EMG-measured TOFR
(Fig. 3). CART analysis showed that EMG-values could
Fig. 3 Specification of eight clinical tests in relation to the Train-of-Four Ratio (TOFR) as measured by electromyography
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be predicted with three tests only (Fig. 4). In the first
step, the variable “arm lift” divided the set of patients
at a cut-off point of 5 s. Both subsets were further
split by the variable “head lift”. Patients, who could
not lift their arm for 5 s and their head for at least
2 s (node 3), had in 22 of 25 cases (88%) an EMG-
measured TOFR <0.3. Patients who were able to lift
the arm for 5 s, to lift the head for 5 s, and to swal-
low 20 ml of water without any restriction (node 11)
had in 41 of 43 cases (95%) an EMG-measured TOFR
>0.7 and in 30 cases (74%) an EMG-measured TOFR
>0.9. Finally, CART resulted in six decision pathways
(Fig. 4: node 3, node 5, node 6, node 8, node 10, and
node 11).
For cut-off points TOFR <0.9 and TOFR <0.7 ROC-
curves were calculated and the corresponding values
of the algorithm of muscle function tests were com-
pared with AMG (Fig. 5). There was no significant
difference between the AMG-measurement and the
algorithm of muscle function tests regarding the AUC
of the ROC curves.
Validation
In order to validate the three tools to identify TOFR <0.9
and TOFR <0.7, a separate set of 118 patients were enrolled,
of which 100 patients were analysed (age: 39 ± 12 years;
weight: 76 ± 14 kg; body mass index (BMI) 25 ± 3 kg/m2).
Two patients had to be excluded due to unexpected intraoral
surgery and 16 because of loss of EMG signal quality during
emergence from anaesthesia. The neuromuscular block at
the time of assessment is given in Table 2. Following clinical
assessment, 62 of the 100 patients required reversal with
neostigmine. After 30 min in the PACU, no patient had clin-
ical signs of neuromuscular weakness. Prediction coefficients
reveal an advantage of the uncalibrated AMG compared to
the algorithm of muscle function tests in terms of specificity
to identify the EMG-measured TOFR <0.7 (89.7% vs. 34,5%)
and TOFR <0.9 (100% vs. 42.9%). While the latter has a
higher sensitivity in comparison to the uncalibrated AMG at
TOFR <0.7 (100% vs. 94.4%) (Table 3).
Figure 6 shows the calculated risk to ignore a residual
block of TOFR <0.7 and TOFR <0.9 with a PNS, an uncal-
ibrated AMG and the algorithm of muscle function tests.
Fig. 4 Regression analysis with classification and regression tree (CART). The upper section of the figure depicts how CART revealed six nodes of test
scores that significantly divide the collective regarding the TOFR measured by calibrated electromyography (EMG). The lower section of the figure shows
boxplots of EMG measured TOFR in patients allocated to the respective nodes. The test combinations of node 11 (arm lift ≥5 s, head lift ≥5 s, and
swallowing without any hindrance) was able to discriminate between patients with TOFR <0.7 and TOFR ≥0.7
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TOFR >0.9 is always ignored with PNS related techniques
(risk = 100%) due to the specificity = 0 (Table 3) of the
tool at this TOFR. Following an uncalibrated AMG mea-
sured TOFR >0.9, a patient has the lowest risk to actually
have a TOFR <0.9. The sensitivity of the muscle function
algorithm for TOFR <0.7 (=100%) reduces the risk to 0 for
a patient, who successfully passes head lift, arm lift and
swallowing, to be at TOFR <0.7.
Discussion
Residual neuromuscular block in awake patients can be
validly identified with an uncalibrated AMG. For the first
time we could demonstrate that the combination of four
muscle function tests, including duration of arm lift, dur-
ation of head lift, duration to keep the eyes open, and abil-
ity to swallow 20 ml of water, has a discriminative power
comparable to the TOFR of an uncalibrated AMG. Based
on three of these tests, an algorithm was developed, which
is able to identify patients with a TOFR <0.7 and, with re-
strictions, a TOFR <0.9.
There is no doubt that calibrated, quantitative neuro-
muscular monitoring is the gold standard to measure
neuromuscular function during anaesthesia and before
extubation [21]. Intuitively, one may also prefer common
quantitative neuromuscular monitoring in the PACU. In
awakening or awake patients after anaesthesia, however,
there is no evidence about its quality irrespectively its
complex applicability [11, 13]. Nevertheless, the risk to
overlook residual or reoccurrence of neuromuscular block
after anaesthesia, i.e. in the PACU, necessitates a valid tool
for differential diagnostic reasons [22, 23]. This is under-
girded by the fact that even with the use of sugammadex
without neuromuscular monitoring TOFR in the PACU
still remains less than 0.9 in almost 9.4% [24].
The number of and the reasons for excluded patients in
this study demonstrate the complexity of any neuromus-
cular monitoring technique in awake patients, even when
continued after anaesthesia. All mandatory measures were
applied to guarantee stable measurements of EMG in
order to serve as reference method [19]. In addition, we
performed the measurements during a 30 min extended
stay in the operating room in order to reduce transport re-
lated failures. Nevertheless, we were not able to continue
EMG much less to reliably start AMG monitoring in 26
patients (13.0%). In this cohort of alert, orientated and co-
operative patients, the clinical assessment could not be
completed in 4.5% of the patients only. The most difficult
test to be carried out was the swallowing test.
In the patients, in whom the technical problems could
be controlled, the AMG proved to reproduce the cali-
brated EMG in the best way. This is even more remark-
able, since we mimicked the clinical conditions of a
PACU tool, which cannot be calibrated before relaxation
as a matter of principle. AMG, however, overestimated
the TOFR measured by EMG. This well-known problem
is responsible for the risk to overlook a TOFR <0.9 as
well as a TOFR <0.7 with AMG (Fig. 6) [25]. Based on
Fig. 5 Receiver operated characteristic (ROC) curves to discriminate
electromyography (EMG) measured train-of-four ratio (TOFR) with
uncalibrated AMG and algorithm of muscle function tests. The area
under the curves (AUC) of uncalibrated acceleromyography (AMG)
and the algorithm of muscle function tests did not differ significantly
for TOFR <0.7 (p = 0.094) as well as TOFR <0.9 (p = 0.136)
Table 3 Validation of the muscle function algorithm (head lift, arm lift, swallowing 20 ml water, eye opening), tactile fading after
peripheral nerve stimulation (PNS), and uncalibrated acceleromyography (AMG) to identify patients with TOF < 0.9 or TOF < 0.7 in
the post anaesthesia care unit. Results (with 95% confidence intervals) from a second prospective cohort of 100 patients
Algorithm of muscle function tests Fading following PNS Uncalibrated AMG
TOF < 0.9 Sensitivity 92.5% [85.1; 96.9] 33.7% [24.2; 44.3] 93.6% [86.5; 97.6]
Specificity 42.9% [9.9; 81.6] 0.0% [0.0; 41.0] 100.0% [59.0; 100]
TOF < 0.7 Sensitivity 100% [94.9; 100] 18.8% [10.4; 30.1] 94.4% [86.2; 98.4]
Specificity 34.5% [17.9; 54.3] 16.7% [5.6; 34.7] 89.7% [72.6; 97.8]
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the prevalence reported by Debaene et al., Cammu et al.,
or Murphy et al. an average of 3% – 5% patients must be
expected to have a TOFR <0.9, when AMG indicates a
TOFR ≥0.9, and, more important, up to 1.6% would be
at risk to have a TOFR <0.7, when AMG indicates a
TOFR ≥0.7 (Fig. 6) [15, 18, 26]. Accordingly, we recom-
mend increasing the requested level of TOFR recovery
when using AMG in awake patients analogously to
anaesthetised patients [27, 28].
Tactile neuromuscular monitoring cannot reveal a re-
sidual neuromuscular block with a TOFR between 0.4
and 0.9 in anaesthetised patients [29]. In our study, this
missing discriminative power of tactile evaluation was
confirmed in awake patients. As expected, tactile fading
in the TOF-stimulation pattern is neither able to identify
a TOFR <0.9 nor a TOFR <0.7 in awake patients (Fig. 6).
Studies investigating residual paralysis found a lack of ac-
cordance between individual muscle function tests and un-
calibrated AMG monitoring [14, 15]. We confirmed these
findings demonstrating that single tests reproduced the
well-known varying sensitivity of muscles at arm, neck,
pharynx, and eyes (Fig. 3) [30–33]. Therefore, we used
CART to create a clinically practicable algorithm based on
the muscle function tests. CART splits the entire sample
into two subgroups out of all possible scores searching for
the best separation [20]. As the resulting subgroups are ana-
lysed in the same way independently until either no signifi-
cant split could be performed or the sample became too
small, a hierarchical model is generated. The result of this
modelling has the great advantage of easy applicability with-
out any calculations or technical measurements, simply by
logically combing the assessments. Therefore, minor lack of
discriminative power may be acceptable, because the clinical
practicability effectively increases.
The upper airway function played a key role, when the
level of acceptable TOFR recovery was defined to be 0.9
based on a number of sophisticated studies in volunteers
[32, 34–36]. After a successfully performed 5 s arm and
a 5 s head lift (node 1, node 7), expectedly, the simplistic
test to swallow 20 ml water was not able to discriminate
between TOFR <0.9 and TOFR >0.9 alone. Nevertheless,
the swallowing test contributed to the algorithm exactly
at this TOFR (node 9, Fig. 4).
The high sensitivity (100%) of the algorithm to identify
patients with severe residual paralysis (TOFR <0.7) may
protect affected patients in the PACU to be overlooked,
independent how many patients actually have a TOFR
<0.7 (Fig. 6). Since data on respiratory failure support the
notion that TOFR <0.7 indicates patients, who are at high
and acute risk, the algorithm seems to be an improvement
in terms of safety, identifying severe residual paralysis [2].
The high sensitivity of the algorithm, however, also im-
plies the risk to overestimate residual neuromuscular
block and therefore provoke overtreatment with its im-
manent side effects. High dose cholinesterase inhibitors
like neostigmine applicated at minimal levels of neuro-
muscular block, e.g. may induce nausea and vomiting,
increase airway secretion, and may paradoxically impair
the upper airway muscle function [37, 38].
Residual block with TOFR <0.3 should be recognised be-
fore extubation even without any neuromuscular monitor-
ing. But neither pharmacological reversal with neostigmine
nor with sugammadex based on non-systematic clinical
Fig. 6 Risk to overlook patients with residual neuromuscular
blockade with a TOFR <0.9 and TOFR <0.7 when assessed with
either uncalibrated acceleromyography (AMG), the algorithm of
clinical muscle function tests, or tactile fading following peripheral
nerve stimulation (PNS). The lines represent the mean risk to
overlook residual neuromuscular blockade as a function of its
prevalence. Exemplarily, the risks (bars are the 95% confidence
intervals) are marked based on the prevalence found by Debaene et
al. [25] Cammu et al. [15] and Murphy et al. [18]
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signs of muscle weakness are able to avoid PORC [39]. It
was not our aim to provoke extubation at such deep levels.
The members of the study staff, however, routinely apply
quantitative neuromuscular monitoring when paralyzing
their patients and, therefore, were less experienced to work
without it. Nevertheless, no patient was harmed by one of
the typical complications of a residual block. Although
there was a potential risk of pulmonary aspiration using
the swallowing test (20 ml of water), we observed no makro
aspiration. Mikro aspiration could not be excluded clinic-
ally. This might be due to the short assessment period be-
fore reversal with 40 μg/kg neostigmine, the thorough care
taking by the study staff expecting patients with a residual
block, but also the patients’ preoperative information that
such a scenario might happen.
There are limitations to the present investigation. First, the
algorithm was developed in a well-defined group of patients
(ASA 1, 2) without organ dysfunction. Second, the relatively
young study population (18–65 years) was scheduled just for
elective, low risk, surgical procedures. Third, just short-
acting anesthetic medication (desflurane, remifentanil) was
used, enabling sufficient alertness and cooperation after
extubation for the clinical assessment. Fourth, swallowing of
20 ml water as a part of the algorithm might provoke aspir-
ation in patients with residual paralysis.
Conclusion
We developed and verified tools for the PACU to iden-
tify patients with residual neuromuscular block. AMG,
even when used uncalibrated in awakening patients,
proved to identify a residual neuromuscular block. An
algorithm based on muscle function tests is also able to
indicate residual neuromuscular blocks with high sensi-
tivity for a TOFR <0.7. This tool might reduce the risk
to overlook severe residual neuromuscular block in the
PACU of institutions, in which only qualitative neuro-
muscular monitoring with PNS is used.
Further clinical studies are necessary to test this muscle
function algorithm in other populations (ASA 3–4,
age > 65 years) and varying clinical settings.
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